Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (113)
  • Open Access

    REVIEW

    Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review

    Giacomo Iovane1,*, Luca Traman2, Michele Maffezzoli1,3, Giuseppe Fornarini2, Domenico Corradi4, Debora Guareschi4, Matteo Santoni5,#, Sebastiano Buti1,#

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523 - 30 December 2025

    Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:More > Graphic Abstract

    Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review

  • Open Access

    ARTICLE

    AI-driven radiogenomic analysis of clear cell renal cell carcinoma: perinephric adipose tissue stranding as a key feature of the NIPAL4-associated imaging pattern

    Federico Greco1,2,*, Marco Cataldo3, Valerio D’Andrea2,4, Luca Pugliese5, Andrea Panunzio6, Alessandro Tafuri6, Bruno Beomonte Zobel2,4, Carlo Augusto Mallio2,4

    Canadian Journal of Urology, Vol.32, No.5, pp. 433-443, 2025, DOI:10.32604/cju.2025.068390 - 30 October 2025

    Abstract Background: Radiogenomics offers a non-invasive approach to correlate imaging features with tumor molecular profiles. This study aims to identify computed tomography (CT) imaging characteristics associated with positive NIPA-like domain containing 4 (NIPAL4) expression in clear cell renal cell carcinoma (ccRCC) and to develop a radiogenomic predictive model to support personalized risk stratification. Methods: A retrospective analysis was conducted on 241 ccRCC patients from The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA) databases. Clinical, pathological, and CT features were compared between NIPAL4-positive and NIPAL4-negative groups. A penalized logistic regression model was built to… More >

  • Open Access

    CASE REPORT

    A case report of epithelioid renal angiomyolipoma with inferior vena cava extension: robotic surgical management and literature review of rare presentation

    Dimindra Karki*, Ghizlane Yaakoubi, Beth Edelblute, Ahmed Aboumohamed*

    Canadian Journal of Urology, Vol.32, No.5, pp. 501-507, 2025, DOI:10.32604/cju.2025.063294 - 30 October 2025

    Abstract Background: Epithelioid angiomyolipoma (EAML) is an uncommon renal tumor variant with histologic and radiologic features that can mimic renal cell carcinoma (RCC) on imaging due to the paucity of fat compared to the classic AML. EAML may exhibit aggressive behavior, including local invasion, recurrence, and distant metastases to the liver, lungs, and lymph nodes. Although recent reports suggest that up to one-third of EAML cases may behave malignantly, variability in diagnostic criteria and limited case series contribute to uncertainty regarding its true clinical course. Case Description: This case report describes a 19-year-old female presenting with an… More >

  • Open Access

    ARTICLE

    ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway

    Jiayin Peng1,2,#, Yijun Xue2,#, Zhiren Cai2, Zhaoguan Li2, Kangyan Han2, Xiaoqi Lin2, Yutong Li1,*, Yumin Zhuo1,*

    Oncology Research, Vol.33, No.10, pp. 3127-3154, 2025, DOI:10.32604/or.2025.067340 - 26 September 2025

    Abstract Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor… More >

  • Open Access

    ARTICLE

    IL1A: a novel prognostic biomarker and potential therapeutic target for renal clear cell carcinoma

    JI ZENG1,2,3,#, XUETENG MENG1,3,#, YUAN ZHANG1,3, JUN LI1, TAOTAO MA1,3,4, CHENG HUANG1,3,*

    Oncology Research, Vol.33, No.7, pp. 1739-1755, 2025, DOI:10.32604/or.2025.061978 - 26 June 2025

    Abstract Background: Renal cell carcinoma (RCC) is a prevalent malignancy characterized by a rising incidence and significant mortality. Interleukins (ILs) are crucial in regulating immune cell trafficking and exhibit anti-tumor properties. However, limited research has explored the expression levels and prognostic significance of interleukins in RCC. Methods: In this comprehensive study, we performed a detailed analysis of interleukins in RCC patients using multiple bioinformatics tools, including Oncomine, UALCAN, GEPIA, Kaplan-Meier plotter, cBioPortal, GeneMANIA, TRRUST, STRING, and Linked Omics. Results: Our analysis demonstrated a significant upregulation in the transcriptional levels of IL4, IL7, IL15, IL16, IL23A, IL26, and… More >

  • Open Access

    ARTICLE

    The intersection of histologies: navigating the complexity of a renal collision tumor

    Tatiana Henriksson1,*, Katharina Mitchell2, Reima El Naili3, Ali Hajiran2

    Canadian Journal of Urology, Vol.32, No.2, pp. 95-99, 2025, DOI:10.32604/cju.2025.065002 - 30 April 2025

    Abstract Renal cell carcinoma is a heterogeneous group of renal tumors characterized by several histological subtypes. Herein, we discuss an unusual case of a 55-year-old male who presented as a consultation to our urology clinic with an incidentally found renal mass. After shared decision making patient proceeded with a Robotic Assisted Laparoscopy (RAL) left sided partial nephrectomy. Final pathology confirmed the presence of high nuclear grade mixed clear cell and papillary renal cell carcinoma (RCC) of the left kidney (pT3aN0M0). This case elucidates a very rare incidence of a patient seen to have a collision tumor, More >

  • Open Access

    ARTICLE

    Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI

    Miguel Ángel Gómez-Luque*, Guillermo Lendínez-Cano, Carmen Belén Congregado-Ruiz, Ignacio Osman-García, Rafael Antonio Medina-López

    Canadian Journal of Urology, Vol.32, No.2, pp. 101-109, 2025, DOI:10.32604/cju.2025.063073 - 30 April 2025

    Abstract Introduction: In recent years, significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) have notably extended overall survival (OS) times, particularly with the introduction of tyrosine kinase inhibitors (TKIs) and combination immunotherapy. However, survival outcomes in mRCC remain highly variable. Materials and Methods: This study retrospectively analyzed clinical and demographic factors at diagnosis in patients treated for mRCC to identify predictors of long-term survival (defined as OS ≥ 48 months). Patients were categorized into long-term survivors (LTS) and non-long-term survivors (nLTS). Results: The analysis revealed that factors such as better Karnofsky Performance Status (KPS), More >

  • Open Access

    ARTICLE

    EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway

    NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI*

    Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

    Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

  • Open Access

    ARTICLE

    Circular RNA circAGAP1 promotes sunitinib sensitivity in renal cell carcinoma via sponging multiple PDGFR-targeted miRNAs

    QI LV1,#, GANGMIN WANG2,#, YI HONG1, TIANYI ZHU1, SHUANG QIN1, SAIFEI SUN1, YUTING WANG1, YAOHUA LIU1, QING ZHANG1, CHUNHUI MA3,*, PEIJUN WANG1,*

    Oncology Research, Vol.33, No.2, pp. 407-420, 2025, DOI:10.32604/or.2024.047698 - 16 January 2025

    Abstract Background: Sunitinib resistance is a major challenge in advanced renal cell carcinoma (RCC). Clinically, elucidating the underlying mechanisms and developing practical countermeasures for sunitinib resistance in RCC is desirable. In previous studies, we found that circAGAP1 expression was significantly upregulated in clear cell RCC (ccRCC) and was strongly associated with poor prognosis. However, the role of circAGAP1 in sunitinib resistance in ccRCC remains unclear. Methods: We used public databases for bioinformatics analysis to identify the binding targets of circAGAP1. Additionally, the effects of circAGAP1 on the proliferation, clonogenesis, apoptosis, and migration of ccRCC cells were… More > Graphic Abstract

    Circular RNA circAGAP1 promotes sunitinib sensitivity in renal cell carcinoma via sponging multiple PDGFR-targeted miRNAs

  • Open Access

    REVIEW

    Renal cell carcinoma: entering the age of biomarkers

    Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester

    Canadian Journal of Urology, Vol.31, No.4, pp. 11921-11930, 2024

    Abstract Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.
    Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference… More >

Displaying 1-10 on page 1 of 113. Per Page